Twist Bioscience Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2022 Annual Meeting of Stockholders held on February 8, 2022. The filing covers the voting outcomes for four proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Approximately 92.49% of eligible shares were present or represented by proxy. All four proposals were approved by stockholders:
- Proposal One (Election of Directors): Four Class I directors were elected. Melissa A. Starovasnik received the highest support with 42,463,236 votes for, while Nelson Chan received 20,458,698 votes for.
- Proposal Two (Executive Compensation): The non-binding advisory vote to approve Named Executive Officer compensation passed with 36,736,935 votes for and 5,872,414 votes against.
- Proposal Three (Auditor Ratification): Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered accounting firm for the fiscal year ending September 30, 2022, with 46,858,618 votes for.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the specific terms of the executive compensation package approved in Proposal Two.
- Confirm the tenure and specific responsibilities of the newly elected Class I directors.
- Review the full proxy statement for details on the "Votes Withheld" for director Nelson Chan, which exceeded 22 million shares.